Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 35Breast Neoplasms 34Lung Neoplasms 20Triple Negative Breast Neoplasms 6Neoplasm Metastasis 5Adenocarcinoma of Lung 5Uterine Cervical Neoplasms 4Rhabdomyosarcoma 3Neoplasms 3NSCLC 3Hodgkin Disease 3Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma, Alveolar 2Recurrence 2Adenocarcinoma 2Thoracic Neoplasms 1Sarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non - Small Cell Lung Cancer NSCLC 1Neuralgia 1Metastatic HER2-positive Breast Cancer 1Mesothelioma, Malignant 1Malignant mesenchymal tumor 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Diseases 1HR+HER2- Breast Cancer 1HER2-positive Advanced Breast Cancer 1

Interventions

eribulin 1Vinorelbine 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HR+HER2- Breast Cancer × Vinorelbine × Clear all
NCT06343948 2026-04-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
383 enrolled
Breast

HR+HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡